Pyrogenic Risk Assessment

In alignment with the modern regulatory philosophy of Ph. Eur. 5.1.13, ensuring product safety now requires a holistic Pyrogenic Risk Assessment that moves beyond simple endotoxin screening to evaluate the entire manufacturing value chain for both endotoxins and Non-Endotoxin Pyrogens (NEPs). While traditional BET and sustainable rFC (Ph. Eur. 2.6.32) methods are highly effective for Gram-negative contaminants, they possess a critical safety blind spot regarding NEPs from Gram-positive bacteria, viruses, and fungi. To bridge this gap, CellMade utilizes the Monocyte Activation Test (MAT), the only compendial assay (Ph. Eur. 2.6.30) that mimics the human innate immune response by measuring cytokine release (IL-1, IL-6, TNF-α) triggered via Toll-like receptors. By integrating specialized tools like the EndoLISA® assay for interfering matrices and providing technical mastery in complex biologics and ATMPs, we help manufacturers map contamination risks, evaluate process clearance, and implement a scientifically justified control strategy that fulfills the mandatory transition away from animal-based testing while ensuring absolute patient safety.